Abiopharma

ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue

Schrödinger, Inc. - Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

Allurion - Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Mirum Pharma - Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum

(85% Positive) Sonoma Pharmaceuticals Inc. (SNOA) Files Form 8-K

(30% Negative) Clene Inc. (CLNNW) Announces Clinical Trial Timeline Adjustment

Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting